<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04131959</url>
  </required_header>
  <id_info>
    <org_study_id>2018-002</org_study_id>
    <secondary_id>IRAS project ID 264064</secondary_id>
    <nct_id>NCT04131959</nct_id>
  </id_info>
  <brief_title>Ticagrelor CytoSorb Hemoadsorption</brief_title>
  <acronym>TISORB</acronym>
  <official_title>Ticagrelor CytoSorb Hemoadsorption (TISORB): Prospective, Open, Multi-center, Single-arm Study to Demonstrate the Feasibility of the CytoSorb® 300 mL Device to Remove Ticagrelor During Cardiopulmonary Bypass in Patients on Ticagrelor Undergoing Emergent Cardiothoracic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CytoSorbents, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CytoSorbents, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      TISORB is a study to show that the CytoSorb device removes ticagrelor from blood during
      surgery in patients who need emergency surgery on their heart. The hypothesis of TISORB is
      that removal of ticagrelor by the CytoSorb device during surgery will decrease the risk for
      surgical bleeding from ticagrelor.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 29, 2019</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, open, multi-center, single arm study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary pharmacodynamic endpoint</measure>
    <time_frame>Immediately before and after cardiopulmonary bypass</time_frame>
    <description>Change in platelet reactivity immediately before and after cardiopulmonary bypass</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary pharmacokinetic endpoint</measure>
    <time_frame>Immediately before and after cardiopulmonary bypass</time_frame>
    <description>Change in ticagrelor blood concentration immediately before and after cardiopulmonary bypass</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Emergent Cardiothoracic Surgery</condition>
  <condition>Bleeding</condition>
  <condition>Drug Removal</condition>
  <arm_group>
    <arm_group_label>Pharmacodynamic population</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CytoSorb 300 mL device</intervention_name>
    <description>Intra-operative CytoSorb hemoadsorption of ticagrelor during cardiopulmonary bypass</description>
    <arm_group_label>Pharmacodynamic population</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Cardiothoracic surgery requiring cardiopulmonary bypass ≤ 48 hours following the last dose
        of ticagrelor.

        Exclusion Criteria:

        Any cardiothoracic surgery &gt; 48 hours after last dose of ticagrelor.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tom Clutton-Brock, MB, ChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>NIHR Trauma Management, MedTech Cooperative</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ola Ogunsakin, MD</last_name>
    <phone>+1 504-715-5677</phone>
    <email>oogunsakin@cytosorbents.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ola Ogunsakin, MD</last_name>
      <phone>+1 504-715-5677</phone>
      <email>oogunsakin@cytosorbents.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Blackpool Victoria Hospital</name>
      <address>
        <city>Blackpool</city>
        <state>England</state>
        <zip>FY3 8NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ola Ogunsakin, MD</last_name>
      <phone>+1 504-715-5677</phone>
      <email>oogunsakin@cytosorbents.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harefield Hospital</name>
      <address>
        <city>Harefield</city>
        <state>England</state>
        <zip>UB9 6JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ola Ogunsakin, MD</last_name>
      <phone>+1 504-715-5677</phone>
      <email>oogunsakin@cytosorbents.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ola Ogunsakin, MD</last_name>
      <phone>+1 504-715-5677</phone>
      <email>oogunsakin@cytosorbents.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <state>Scotland</state>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ola Ogunsakin, MD</last_name>
      <phone>+1 504-715-5677</phone>
      <email>oogunsakin@cytosorbents.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ola Ogunsakin, MD</last_name>
      <phone>+1 504-715-5677</phone>
      <email>oogunsakin@cytosorbents.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Golden Jubilee National Hospital</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G81 4DY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ola Ogunsakin, MD</last_name>
      <phone>+1 504-715-5677</phone>
      <email>oogunsakin@cytosorbents.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 15, 2019</study_first_submitted>
  <study_first_submitted_qc>October 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2019</study_first_posted>
  <last_update_submitted>March 5, 2020</last_update_submitted>
  <last_update_submitted_qc>March 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

